Sift Biosciences

Executive Summary

Sift Biosciences is a private biotechnology company headquartered in Cambridge, United States, leveraging artificial intelligence to decode microbial signals for the development of novel immunotherapies. Founded in 2018, the company integrates AI, metagenomics, and high-throughput T-cell screening to identify microbially derived peptides capable of amplifying immune responses, with a focus on treating cancers and autoimmune diseases. Currently in Phase 1 development, Sift Biosciences aims to create targeted treatments by harnessing the body's natural immune mechanisms. Despite being at an early stage, the company's innovative platform positions it as a potential leader in the emerging field of microbiome-based immunotherapy. However, its private status and lack of disclosed funding or valuation data introduce uncertainty, warranting close monitoring of clinical and partnership developments.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial for Lead Candidate70% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference85% success
• Q4 2026Announcement of Strategic Partnership or Licensing Deal40% success